Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 95
Filtrar
1.
Artículo en Inglés | MEDLINE | ID: mdl-38525948

RESUMEN

AIMS: Current assessment of myocardial ischaemia from stress perfusion cardiovascular magnetic resonance (SP-CMR) largely relies on visual interpretation. This study investigated the use of high-resolution free-breathing SP-CMR with automated quantitative mapping in the diagnosis of coronary artery disease (CAD). Diagnostic performance was evaluated against invasive coronary angiography (ICA) with fractional flow reserve (FFR) measurement. METHODS & RESULTS: Seven-hundred and three patients were recruited for SP-CMR using the research sequence at 3 Tesla. Of those receiving ICA within 6 months, 80 patients either had FFR measurement, or identification of a chronic total occlusion (CTO) with inducible perfusion defects seen on SP-CMR. Myocardial blood flow (MBF) maps were automatically generated in-line on the scanner following image acquisition at hyperaemic stress and rest, allowing myocardial perfusion reserve (MPR) calculation. 75 coronary vessels assessed by FFR, and 28 vessels with CTO were evaluated at both segmental and coronary territory level. Coronary territory stress MBF and MPR were reduced in FFR-positive (≤ 0.80) regions (median stress MBF: 1.74 [0.90-2.17] ml/min/g; MPR: 1.67 [1.10-1.89]) compared with FFR-negative regions (stress MBF: 2.50 [2.15-2.95] ml/min/g; MPR 2.35 [2.06-2.54] p < 0.001 for both). Stress MBF ≤ 1.94 ml/min/g and MPR ≤ 1.97 accurately detected FFR-positive CAD on a per-vessel basis (area under the curve: 0.85 and 0.96 respectively; p < 0.001 for both). CONCLUSIONS: A novel scanner-integrated high-resolution free-breathing SP-CMR sequence with automated in-line perfusion mapping is presented which accurately detects functionally significant CAD.

3.
J Pediatr Urol ; 15(1): 72.e1-72.e7, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30477994

RESUMEN

BACKGROUND: Ectopic upper-pole (UP) ureters in duplex kidneys can be managed surgically by ipsilateral distal ureteroureterostomy (U-U) with or without ureteric stenting. Evidence to support routine stenting during this procedure is lacking. OBJECTIVE: The authors present their outcomes of children with ectopic UP ureters who underwent ipsilateral distal U-U. They also compared outcomes of those who underwent routine ureteric stenting to those who did not. STUDY DESIGN: Between 2009 and 2015, the authors performed a prospective analysis on consecutive patients with duplex collecting systems who underwent distal U-U via an inguinal incision for ectopic UP ureters by one of two pediatric urologists. The demographic information, operative factors, and any postoperative complications on follow-up were recorded. RESULTS: The study included 47 patients (28 female) who underwent distal U-U with a mean age of 9.8 months. There were 30 patients who were routinely stented, and 17 who were not based on the routine practices of the operating surgeons without any selection bias. The mean operative time was 90 min, and the mean hospital stay was 0.9 days. No major complications were observed in this series, with 96% of patients showing resolution of hydronephrosis. There were no statistical differences between the stented and stentless U-U groups in terms of operative time, hospital stay, hydronephrosis resolution, time to resolution of hydronephrosis, and major complications. Only stented patients were found to have minor complications (2-urinary tract infection, 2-dysuria, and 2-stent displacement). All patients who underwent routine stent placement required a secondary planned procedure under general anesthesia for the cystoscopic removal of stent. CONCLUSION: Stenting was associated with a higher number of minor complications compared to the stentless group and thus, may not be routinely necessary when performing distal U-U for management of UP ectopic ureters associated with duplicated collecting systems.


Asunto(s)
Stents , Uréter/anomalías , Uréter/cirugía , Ureterostomía/métodos , Femenino , Humanos , Lactante , Masculino , Complicaciones Posoperatorias/epidemiología , Estudios Prospectivos
4.
J Mol Endocrinol ; 50(3): 337-46, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23475748

RESUMEN

Glucose-controlled insulin secretion is a key component of its regulation. Here, we examined whether liver cell secretion of insulin derived from an engineered construct can be regulated by glucose. Adenovirus constructs were designed to express proinsulin or mature insulin containing the conditional binding domain (CBD). This motif binds GRP78 (HSPA5), an endoplasmic reticulum (ER) protein that enables the chimeric hormone to enter into and stay within the ER until glucose regulates its release from the organelle. Infected HepG2 cells expressed proinsulin mRNA and the protein containing the CBD. Immunocytochemistry studies suggested that GRP78 and proinsulin appeared together in the ER of the cell. The amount of hormone released from infected cells varied directly with the ambient concentration of glucose in the media. Glucose-regulated release of the hormone from infected cells was rapid and sustained. Removal of glucose from the cells decreased release of the hormone. In streptozotocin-induced diabetic mice, when infected with adenovirus expressing mature insulin, glucose levels declined. Our data show that glucose regulates release of exogenously expressed insulin from the ER of liver cells. This approach may be useful in devising new ways to treat diabetes mellitus.


Asunto(s)
Diabetes Mellitus/metabolismo , Glucosa/farmacología , Insulina/metabolismo , Animales , Modelos Animales de Enfermedad , Chaperón BiP del Retículo Endoplásmico , Glucosa/metabolismo , Proteínas de Choque Térmico/metabolismo , Células Hep G2 , Humanos , Ratones
5.
Int J Soc Psychiatry ; 59(2): 176-87, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22219173

RESUMEN

BACKGROUND: Service user participation in direct service provision and evaluation has been developing in the western world in the past 20 years. However, this recovery-based care model is relatively new in Asia. AIM: To understand the views and perceptions of the service users and of psychiatric nurses about the recruitment of peer specialists in a regional psychiatric unit in Hong Kong. METHOD: A qualitative study using probe questions to understand the above issues in the form of focus group discussion. A total of 13 psychiatric nurses and 16 mental health service users were recruited from a regional psychiatric unit for the study. RESULTS: Content analysis based loosely on grounded theory has identified several important themes. While service users are generally enthusiastic about the potential contribution of peer specialists in a service setting, they are much concerned about rejection and discrimination by the psychiatric staff. Psychiatric nurses are also sceptical about the involvement of peer specialists in the delivery of service, although for an entirely different set of reasons. In view of the divergent views of the service users and the psychiatric nurses, a second round of focus group discussion was conducted seven months later to understand whether the themes distilled were consistent with their views expressed in the first round of focus group discussion. CONCLUSION: It is encouraging is that, for those psychiatric nurses who worked with volunteer service users in the pilot scheme of 'expert user participation', there was a change in view towards positive acceptance about peer specialist involvement in service delivery. The study provides some insight into the potential obstacles to and opportunities in the implementation of peer specialist services in routine psychiatric services in Hong Kong.


Asunto(s)
Atención a la Salud/métodos , Testimonio de Experto/métodos , Trastornos Mentales , Participación del Paciente , Revisión por Expertos de la Atención de Salud/métodos , Enfermería Psiquiátrica , Adulto , Actitud del Personal de Salud , Servicios Comunitarios de Salud Mental/organización & administración , Investigación Participativa Basada en la Comunidad , Estudios Transversales , Femenino , Grupos Focales , Hong Kong , Humanos , Masculino , Trastornos Mentales/diagnóstico , Trastornos Mentales/terapia , Persona de Mediana Edad , Prioridad del Paciente , Investigación Cualitativa
7.
Mol Hum Reprod ; 14(9): 547-54, 2008 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-18708652

RESUMEN

Human placentation displays many similarities with tumourigenesis, including rapid cell division, migration and invasion, overlapping gene expression profiles and escape from immune detection. Recent data have identified promoter methylation in the Ras association factor and adenomatous polyposis coli tumour suppressor genes as part of this process. However, the extent of tumour-associated methylation in the placenta remains unclear. Using whole genome methylation data as a starting point, we have examined this phenomenon in placental tissue. We found no evidence for methylation of the majority of common tumour suppressor genes in term placentas, but identified methylation in several genes previously described in some human tumours. Notably, promoter methylation of four independent negative regulators of Wnt signalling has now been identified in human placental tissue and purified trophoblasts. Methylation is present in baboon, but not in mouse placentas. This supports a role for elevated Wnt signalling in primate trophoblast invasiveness and placentation. Examination of invasive choriocarcinoma cell lines revealed altered methylation patterns consistent with a role of methylation change in gestational trophoblastic disease. This distinct pattern of tumour-associated methylation implicates a coordinated series of epigenetic silencing events, similar to those associated with some tumours, in the distinct features of normal human placental invasion and function.


Asunto(s)
Metilación de ADN , Placenta/metabolismo , Trofoblastos/metabolismo , Animales , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico/genética , Proteínas Portadoras/genética , Línea Celular Tumoral , Células Cultivadas , Proteínas de Unión al ADN , Factores de Transcripción de la Respuesta de Crecimiento Precoz/genética , Femenino , Humanos , Receptores de Hialuranos/genética , Técnicas In Vitro , Proteínas de la Membrana/genética , Ratones , Neoplasias/genética , Neoplasias/patología , Papio , Embarazo , Primer Trimestre del Embarazo , Proteínas Represoras/genética , Trofoblastos/citología , Proteínas Supresoras de Tumor/genética
8.
Cancer Lett ; 268(1): 56-62, 2008 Sep 08.
Artículo en Inglés | MEDLINE | ID: mdl-18485586

RESUMEN

Methylation of the human APC gene promoter is associated with several different types of cancers and has also been documented in some pre-cancerous tissues. We have examined the methylation of APC gene promoters in human placenta and choriocarcinoma cells. This revealed a general hypomethylation of the APC-1b promoter and a pattern with monoallelic methylation of the APC-1a promoter in full term placental tissue. However, there was no evidence of a parent-of-origin effect, suggesting random post zygotic origin of methylation. Increased methylation of this promoter was observed in all choriocarcinoma-derived trophoblast cell lines, suggesting a trophoblastic origin of placental APC methylation and implicating APC hypermethylation in the development of this group of gestational tumours. Our demonstration of placental methylation of the APC-1a promoter represents the first observation of monoallelic methylation of this gene in early development, and provides further support for a role of canonical Wnt signalling in placental trophoblast invasiveness. This also implicates tumour suppressor gene silencing as an integral part of normal human placental development.


Asunto(s)
Coriocarcinoma/genética , Metilación de ADN , Genes APC , Placenta/metabolismo , Línea Celular Tumoral , Coriocarcinoma/metabolismo , Femenino , Silenciador del Gen , Humanos , Regiones Promotoras Genéticas
9.
Gut ; 57(5): 664-71, 2008 May.
Artículo en Inglés | MEDLINE | ID: mdl-17998316

RESUMEN

BACKGROUND: Infection with the hepatitis C virus (HCV) causes acute hepatitis. This disease has a high probability of becoming chronic and leading to cirrhosis, but a more deadly consequence is hepatocellular carcinoma. Interferon alpha (IFN alpha)-based treatment combined with ribavirin is the major therapeutic choice available for the treatment of chronic HCV infection. AIMS: The scavenger receptor class B type I (SR-BI) or its human homologue CD36 and LIMPII Analogous-1 (hSR-BI/CLA-1) has recently been shown to interact with HCV envelope glycoprotein E2, thus suggesting that it might participate in entry of the virus into host cells. This rationale underlies current interest in the potential role of IFN alpha in hSR-BI/CLA-1 expression in HepG2 cells. RESULTS: It was shown that endogenous hepatocyte expression of hSR-BI/CLA-1 was suppressed by exposure to IFN alpha. Decreased hSR-BI/CLA-1 expression in IFN alpha-treated cells was due to lower transcriptional activity of the promoter. A potential pathway for the effect of IFN alpha on hSR-BI/CLA-1 promoter activity was identified when the inhibitory action of IFN was abrogated in signal transducer and activator of transcription 1 (STAT1)/STAT2 knocked-down cells. Exposure of HepG2 cells to IFN alpha elicited a rapid phosphorylation of STAT1/STAT2, a known target of IFN alpha signalling. In addition, the mutagenesis of a STAT1/STAT2 response element in the hSR-BI/CLA-1 promoter abolished the ability of IFN alpha to suppress promoter activity. CONCLUSIONS: Together, these results indicate that the STAT1/STAT2 pathway participates in IFN alpha inhibition of hSR-BI/CLA-1 expression, and raise the possibility that lowering the expression of this gene may be of therapeutic value for treating HCV infections.


Asunto(s)
Antivirales/farmacología , Hepacivirus/metabolismo , Hepatitis C/metabolismo , Interferón-alfa/farmacología , Receptores Virales/antagonistas & inhibidores , Receptores Depuradores de Clase B/antagonistas & inhibidores , Antígenos CD/metabolismo , Western Blotting , Células Cultivadas , ADN Viral/metabolismo , Femenino , Regulación de la Expresión Génica/fisiología , Hepatitis C/tratamiento farmacológico , Hepatocitos/metabolismo , Hepatocitos/virología , Humanos , Masculino , ARN Viral/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Receptores Depuradores de Clase B/metabolismo , Tetraspanina 28 , Proteínas Virales/efectos de los fármacos , Replicación Viral/efectos de los fármacos
10.
Diabetologia ; 49(7): 1599-607, 2006 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-16752178

RESUMEN

AIMS/HYPOTHESIS: Prolactin regulatory element binding (PREB) protein has been identified as a factor that regulates prolactin promoter activity in rat anterior pituitary. PREB is located not only in the anterior pituitary but also in pancreas; however its role in the pancreas is not known. We therefore examined the role of PREB in insulin gene expression. MATERIALS AND METHODS: To analyse the effects of PREB on insulin gene transcription, we employed the luciferase reporter gene assay and electrophoretic mobility shift assay (EMSA). In cells expressing or knocked down for PREB, insulin expression and secretion were determined. RESULTS: PREB was located mainly in nuclei of rat pancreatic beta cells and its cell line, INS-1. A nuclear extract of INS-1 cells contained material that was recognised by PREB antiserum. This nuclear extract also showed insulin promoter binding activity that was super-shifted by PREB antiserum in EMSA studies. In the INS-1 cells, co-expression of PREB and the insulin promoter induced activity of the latter. The addition of glucose to the cells increased PREB expression. Deletional analysis of the insulin promoter showed that A3, a glucose-responsive cis-element in the insulin promoter, mediated the transcriptional effect of PREB. In addition, synthesised PREB bound the A3 element by EMSA, while a mutant of this motif in the insulin promoter abrogated the effect of PREB. Cells expressing or knocked down for PREB exhibited increased or decreased insulin expression, respectively. CONCLUSIONS/INTERPRETATION: These results demonstrate that PREB may contribute to the regulation of insulin gene transcription and insulin secretion in response to glucose stimulation.


Asunto(s)
Proteínas de Unión al ADN/fisiología , Regulación de la Expresión Génica/efectos de los fármacos , Glucosa/farmacología , Factores de Intercambio de Guanina Nucleótido/fisiología , Insulina/genética , Factores de Transcripción/fisiología , Animales , Sitios de Unión , Células COS , Células Cultivadas , Chlorocebus aethiops , Proteínas de Unión al ADN/metabolismo , Factores de Intercambio de Guanina Nucleótido/metabolismo , Insulina/biosíntesis , Insulina/metabolismo , Secreción de Insulina , Islotes Pancreáticos/metabolismo , Ratones , Regiones Promotoras Genéticas , Ratas , Ratas Wistar , Factores de Transcripción/metabolismo
11.
J Mol Endocrinol ; 32(2): 497-505, 2004 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15072554

RESUMEN

The thymus contains many apoptotic cells that arise from the process of positive and negative selection. Both thymic macrophages and thymic nurse cells/nursing thymic epithelial cells (nursing TECs), non-professional phagocytes, recognize and ingest apoptotic cells without inflammation or tissue damage. Previously we reported that human scavenger receptor class B (SR-B1) is involved in recognition of apoptotic thymocytes by nursing TECs. In this study, we examined the expression and role of a phosphatidylserine receptor (PSR). This receptor is believed to participate in the clearance of apoptotic cells. PSR was strongly expressed in nursing TECs. Transforming growth factor-beta augmented the expression of PSR leading to enhanced binding of apoptotic cells to nursing TECs. In nursing TECs, suppressed expression of human SR-B1 with anti-PSR antibody decreased binding of apoptotic thymocytes to nursing TECs. Our results suggest that both PSR and SR-B1 are expressed in nursing TECs and these receptors appear to play a major role in the clearance of apoptotic cells from the thymus.


Asunto(s)
Apoptosis/fisiología , Lipoproteínas HDL/metabolismo , Receptores de Superficie Celular/metabolismo , Receptores de Lipoproteína/metabolismo , Timo/citología , Timo/metabolismo , Animales , Células Cultivadas , Citocinas/farmacología , Células Epiteliales/metabolismo , Femenino , Humanos , Histona Demetilasas con Dominio de Jumonji , Lipoproteínas HDL/genética , Ratones , Ratones Endogámicos BALB C , Oligonucleótidos Antisentido/farmacología , Receptores de Superficie Celular/genética , Receptores Inmunológicos/genética , Receptores Inmunológicos/metabolismo , Receptores de Lipoproteína/genética , Receptores Depuradores , Receptores Depuradores de Clase B , Timo/efectos de los fármacos
12.
J Mol Endocrinol ; 29(3): 265-79, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12459029

RESUMEN

Sp1 is a ubiquitous nuclear factor that plays a key role in maintaining basal transcription of 'house-keeping' genes. However, recent evidence points to a more important function for Sp1 in mediating 'cross-talk' between selected signaling cascades to regulate the target genes that respond to these pathways. The role of Sp1 in mediating the actions of the peptide hormone insulin is of specific interest and serves as a model for detailing effects of intracellular signaling on Sp1 activity. This review summarizes studies suggesting that changes in Sp1 phosphorylation provide one potential mechanism for manipulating activity of this protein. A growing body of evidence reveals that the DNA binding and transcription activity of Sp1 may increase or decrease in response to changes in phosphorylation. This enables 'fine-tuning' of Sp1 activity for regulation of gene transcription. Several mechanisms exist by which Sp1 alters gene activity in response to insulin. These include independent Sp1 activity as well as collaboration or competition with others factors. This review points to an ever-increasing role for Sp1 in regulating the transcription of genes in response to extracellular signals such as insulin.


Asunto(s)
Regulación de la Expresión Génica , Insulina/metabolismo , Factor de Transcripción Sp1/metabolismo , Animales , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Insulina/farmacología , Transducción de Señal/efectos de los fármacos , Transcripción Genética/efectos de los fármacos
13.
J Mol Endocrinol ; 29(3): 297-304, 2002 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-12459032

RESUMEN

Menin is a protein encoded by the gene mutated in multiple endocrine neoplasia type 1 (MEN1) characterized by multiple endocrine tumors of the parathyroid glands, pancreatic islets and the anterior pituitary, especially prolactinoma. In this study, we examined the effects of menin on human prolactin (hPRL) expression. In rat pituitary GH3 cells stably expressing menin, both PRL gene expression/secretion and thymidine incorporation into DNA were inhibited as compared with mock-transfected cells. The transcriptional activity of PRL promoter in GH3 cells co-transfected with menin was significantly decreased. A deletion mutation (569 delC), which we identified in a Japanese MEN1 family, was introduced into menin. When GH3 cells were transfected with a mutant menin expression vector, inhibition of hPRL promoter activity was partially reversed. These observations suggest that menin inhibits hPRL promoter activity and cell proliferation, raising the possibility that menin might play an important role in the tumorigenesis of prolactinoma.


Asunto(s)
Regulación hacia Abajo , Proteínas de Neoplasias/metabolismo , Prolactina/genética , Regiones Promotoras Genéticas/genética , Proteínas Proto-Oncogénicas , Animales , Western Blotting , División Celular , Línea Celular , Regulación Neoplásica de la Expresión Génica , Humanos , Neoplasia Endocrina Múltiple Tipo 1/genética , Proteínas de Neoplasias/genética , Prolactina/metabolismo , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Transcripción Genética , Transfección
14.
Arterioscler Thromb Vasc Biol ; 21(10): 1592-7, 2001 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11597931

RESUMEN

The growth arrest-specific gene 6 encodes a secreted protein, Gas6, which was originally identified as the ligand of a receptor, Axl, with tyrosine kinase activity. The class A scavenger receptor (SRA) mediates lipid uptake into cells, leading to the formation of foam cells, an important step in atherogenesis. Although Gas6 induces SRA expression, the underlying mechanism is not clear. In this report, we show that the Gas6-induced expression of SRA was mediated by the phosphatidylinositol 3-OH kinase (PI3-kinase)-serine/threonine kinase (Akt/protein kinase B [PKB]) pathway involving Akt phosphorylation. This pathway was activated by exposure to Gas6. Furthermore, the effect of Gas6 was abrogated by wortmannin, a specific inhibitor of PI3-kinase. We also demonstrated that the constitutively active form of Akt enhanced activity of the SRA promoter but that the dominant-negative mutant of Akt completely abolished the expression of SRA after treatment with Gas6. These results show that the PI3-kinase-Akt/PKB pathway participates in Gas6-induced SRA expression and suggests that the activation of Akt/PKB plays an important role in Gas6-induced atherosclerosis and foam cell formation in human vascular smooth muscle cells.


Asunto(s)
Antígenos CD36/genética , Péptidos y Proteínas de Señalización Intercelular , Músculo Liso Vascular/metabolismo , Fosfatidilinositol 3-Quinasas/fisiología , Proteínas Serina-Treonina Quinasas , Proteínas/farmacología , Proteínas Proto-Oncogénicas/fisiología , Androstadienos/farmacología , Antígenos CD36/biosíntesis , Línea Celular Transformada , Células Cultivadas , Inhibidores Enzimáticos/farmacología , Humanos , Cinética , Lipoproteínas LDL/metabolismo , Músculo Liso Vascular/efectos de los fármacos , Proteínas Oncogénicas/fisiología , Inhibidores de las Quinasa Fosfoinosítidos-3 , Fosforilación , Regiones Promotoras Genéticas , Transporte de Proteínas , Proteínas Proto-Oncogénicas c-akt , Proteínas Tirosina Quinasas Receptoras/fisiología , Receptores Depuradores de Clase A , Transducción de Señal , Wortmanina , Tirosina Quinasa del Receptor Axl
15.
Biochem Biophys Res Commun ; 287(1): 160-72, 2001 Sep 14.
Artículo en Inglés | MEDLINE | ID: mdl-11549270

RESUMEN

Glucocorticoids inhibit rodent alpha-fetoprotein (AFP) gene activity but stimulate expression of the human homologue. Like human, activity of the AFP promoter from other primates was stimulated by the synthetic glucocorticoid dexamethasone (Dex) in various cell lines. A glucocorticoid responsive element (GRE) is located within 180 bp upstream of the transcription initiation site of all AFP genes examined. Comparative analysis of the GRE in the two different groups of promoters revealed a common 3' hexamer, 5'-TGTCCT-3', but the 5' hexamers were different. This difference converts the rodent GRE to a DR-1 motif. DR-1 is a binding site for members of the nuclear receptor superfamily including the orphan receptor hepatocyte nuclear factor-4 (HNF-4). The presence of DR-1 in the rodent but not human may underlie the opposite actions of Dex on the AFP promoter. We tested this hypothesis using a transient transfection assay. In hepatoma cells that expressed GR and HNF-4, reporter-activity was inhibited by Dex. The same construct in nonhepatoma cells was strongly induced by over expression of HNF-4 and the induced activity was inhibited by Dex. The findings show that Dex induction of human AFP is mediated by a GRE. But Dex repression of the rodent promoter requires a DR-1 motif that interacts with GR and HNF-4.


Asunto(s)
Proteínas de Unión al ADN , Dexametasona/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Glucocorticoides/farmacología , Regiones Promotoras Genéticas/efectos de los fármacos , alfa-Fetoproteínas/genética , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice , Sitios de Unión , Células COS , Dimerización , Silenciador del Gen/efectos de los fármacos , Glutatión Transferasa/genética , Glutatión Transferasa/metabolismo , Gorilla gorilla , Factor Nuclear 4 del Hepatocito , Humanos , Hígado/efectos de los fármacos , Hígado/fisiología , Ratones , Datos de Secuencia Molecular , Pan troglodytes , Fosfoproteínas/metabolismo , Fosfoproteínas/farmacología , Pongo pygmaeus , Ratas , Receptores Citoplasmáticos y Nucleares/metabolismo , Receptores de Glucocorticoides/antagonistas & inhibidores , Receptores de Ácido Retinoico/metabolismo , Receptores X Retinoide , Alineación de Secuencia , Especificidad de la Especie , Factores de Transcripción/metabolismo , Factores de Transcripción/farmacología , Células Tumorales Cultivadas , alfa-Fetoproteínas/biosíntesis
16.
J Mol Endocrinol ; 27(1): 43-57, 2001 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-11463575

RESUMEN

Serum apolipoprotein A(1) (apoA(1)) concentration is inversely correlated with the risk of premature atherosclerosis. Serum apoA(1) concentrations are regulated, in part, at the transcriptional level. ApoA(1) mRNA is synthesized primarily in the liver and small intestine, under the direction of a number of signaling molecules and tissue-specific regulatory elements. Previously, we demonstrated that extracellular acidosis suppresses apoA(1) mRNA levels at the level of transcription. Here we demonstrate that intracellular acidosis, in the absence of extracellular pH changes, represses apoA(1) promoter activity. Repression occurs through a pH responsive element (pH-RE) located within the apoA(1) gene promoter. Acidosis increases the specific DNA binding activity of a putative repressor protein within the immediate 5'-flanking region of the apoA(1) gene. The cis-element that binds the putative repressor protein contains a negative thyroid hormone response element (nTRE) located 3' and adjacent to the apoA(1) TATA box. Mutation of the nTRE/pH-RE abrogates protein binding and alters the activity of reporter genes controlled by this element. Repression by acidosis did not require de novo mRNA and protein synthesis. Inhibition of tyrosine kinase activity and diacylglycerol-stimulated protein kinase C (PKC) signaling pathways with tyrophostin A47 and phorbol myristate acetate, respectively, did not affect the repression of apoA(1) promoter activity with acidosis. These results suggest that transcriptional repression of the apoA(1) gene by alterations in ambient pH is associated with enhanced DNA binding activity of a repressor protein, through a mechanism which appears to be independent of de novo mRNA and protein synthesis, tyrosine kinase activity, or PKC activation.


Asunto(s)
Acidosis/genética , Apolipoproteína A-I/genética , Regulación de la Expresión Génica/fisiología , Proteínas Represoras/fisiología , Secuencia de Bases , Western Blotting , Células Cultivadas , ADN , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Concentración de Iones de Hidrógeno , Ionóforos/farmacología , Mutación , Regiones Promotoras Genéticas , Inhibidores de la Síntesis de la Proteína/farmacología , ARN/farmacología , ATPasa Intercambiadora de Sodio-Potasio/antagonistas & inhibidores , Acetato de Tetradecanoilforbol/farmacología , Tirfostinos/farmacología
17.
Can J Cardiol ; 17(6): 715-21, 2001 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-11420583

RESUMEN

Phytosterol-enriched margarines are a recent addition to the list of so-called 'functional foods'. The ingestion of phyto-sterols lowers the serum cholesterol by inhibiting intestinal uptake of the sterol. The phytosterols available in consumer products are comprised predominantly of beta-sitosterol and sitostanol. The esterified form of these phytosterols increases their solubility and enhances their residence time in the small intestine. Their ability to displace cholesterol from micelles in the small intestine underlies the mechanism that inhibits cholesterol absorption, leading to a 10% reduction in total serum cholesterol. Numerous well designed studies have documented the beneficial actions of these phytosterols on serum cholesterol.


Asunto(s)
Colesterol/metabolismo , Hipercolesterolemia/prevención & control , Fitosteroles/sangre , Fitosteroles/uso terapéutico , Colesterol/sangre , Humanos , Hipercolesterolemia/sangre , Absorción Intestinal
18.
J Clin Endocrinol Metab ; 86(4): 1795-800, 2001 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-11297620

RESUMEN

We studied a 60-yr-old female with a brain tumor who showed severe symptoms of hypoglycemia (plasma glucose, 2.2 mmol/L) and hyperinsulinemia (1.28 nmol/L) after radiotherapy. The cystic brain tumor contained proinsulin and insulin at concentrations of 13.6 and 1.22 nmol/L, respectively. Immunohistochemical studies showed the tumor cells were ectodermal in origin but not endodermal, based on three diagnostic features of neuroectodermal tumors 1) pseudorosette formation noted under light microscopy, 2) finding of a small number of dense core neurosecretory granules on electron microscopy, and 3) positive immunostaining for both neuronal specific enolase and protein gene product 9.5. These cells also expressed the transcription factor, neurogenin-3, NeuroD/beta 2, and islet factor I, which are believed to be transcription factors in neuroectoderm as well as in pancreatic islet cells, but not pancreatic-duodenal homeobox 1, Pax4, or Nkx2.2. In addition, they did not express glucagon, somatostatin, or glucagon-like peptide-1. Our results show the presence of proinsulin in an ectoderm cell brain tumor that does not express the homeobox gene, pancreatic-duodenal homeobox 1, but expresses other transcription factors, i.e. neurogenin3, NeuroD/beta 2, and islet factor-1, which are related to insulin gene expression in the brain tumor.


Asunto(s)
Neoplasias Encefálicas/metabolismo , Proteínas de Homeodominio/metabolismo , Insulina/biosíntesis , Tumores Neuroectodérmicos/metabolismo , Transactivadores/metabolismo , Antígenos de Diferenciación/metabolismo , Factores de Transcripción con Motivo Hélice-Asa-Hélice Básico , Encéfalo/metabolismo , Encéfalo/patología , Neoplasias Encefálicas/patología , Femenino , Proteína Homeobox Nkx-2.2 , Humanos , Proteínas con Homeodominio LIM , Persona de Mediana Edad , Proteínas del Tejido Nervioso/metabolismo , Tumores Neuroectodérmicos/patología , Proteínas Nucleares , Factores de Transcripción , Ubiquitina Tiolesterasa
19.
J Biol Chem ; 276(17): 13822-9, 2001 Apr 27.
Artículo en Inglés | MEDLINE | ID: mdl-11278817

RESUMEN

Insulin induces apolipoprotein A-I, apoA-I gene transcription via a membrane receptor with intrinsic tyrosine kinase activity. This finding prompted us to ask whether the gene is stimulated by epidermal growth factor (EGF), EGF a peptide hormone that binds to another member of the receptor superfamily with tyrosine kinase activity. Our data showed that like insulin, EGF increased abundance of apoA-I protein and transcription of the gene in human hepatoma, Hep G2 cells. The effects of both hormones appeared direct because their induction of apoA-I gene transcription was not affected by the protein synthesis inhibitor, cycloheximide. Although both insulin and EGF stimulate apoA-I expression, each hormone binds to a distinct membrane receptor thus suggesting differential intracellular signaling. Therefore, we used a panel of inhibitors to define the pathway(s) that mediate the actions of these hormones. Whereas, the actions of EGF required only the Ras-mitogen-activated protein, MAP kinase, those of insulin were mediated by equal participation of both the Ras-MAP kinase and protein kinase C, PKC cascades. Despite differences in signaling pathways triggered by each hormone receptor, the activation of apoA-I transcription required the participation of a single transcription factor, Sp1. Furthermore, EGF induction of transcription was attenuated by mutating the MAP kinase site at amino acid, Thr(266) rendering Sp1 phosphorylation deficient. In summary, EGF stimulation of apoA-I expression is mediated solely by the Ras-MAP kinase cascade and enhanced activity of this pathway requires Sp1 with an intact phosphorylation site at Thr(266). However, insulin induction of this gene is different and requires both Ras-MAP kinase and PKC pathways but their actions are also mediated by Sp1.


Asunto(s)
Apolipoproteína A-I/metabolismo , Factor de Crecimiento Epidérmico/metabolismo , Sistema de Señalización de MAP Quinasas , Factor de Transcripción Sp1/metabolismo , Proteínas ras/metabolismo , Secuencia de Aminoácidos , Sitios de Unión , Western Blotting , Cloranfenicol O-Acetiltransferasa/metabolismo , Cicloheximida/farmacología , Electroforesis en Gel de Poliacrilamida , Activación Enzimática , Inhibidores Enzimáticos/farmacología , Receptores ErbB/metabolismo , Genes Dominantes/genética , Genes Reporteros , Genes ras/genética , Humanos , Insulina/metabolismo , Insulina/farmacología , Datos de Secuencia Molecular , Mutagénesis Sitio-Dirigida , Mutación , Fosforilación , Plásmidos/metabolismo , Unión Proteica , Proteína Quinasa C/metabolismo , Inhibidores de la Síntesis de la Proteína/farmacología , Quinazolinas/farmacología , Retroviridae/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Transducción de Señal , Treonina/química , Treonina/genética , Factores de Tiempo , Transcripción Genética , Transfección , Células Tumorales Cultivadas , Regulación hacia Arriba
20.
J Mol Endocrinol ; 25(3): 299-308, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11116209

RESUMEN

We have studied the effects of a cardiac sparing thyromimetic, CGS 23425, on postprandial levels of triglycerides, abundance of apolipoprotein B (apo B) protein and hepatic apo B mRNA expression in rats. When compared with control rats, triglyceride clearance was significantly accelerated by treatment with CGS 23425. A full return to baseline values was achieved within 8 h after ingesting a large quantity of fat, as compared to >24 h in control animals. The abundance of apo B-100 protein in CGS 23425-treated hyperlipidemic rats decreased in a dose-dependent manner, but levels of apo B-48 were not significantly affected. Like L-tri-iodothyronine (L-T(3)), treatment with 30 microg/kg CGS 23425 for 6 or 9 days decreased the levels of apo B-100 protein by 80% and 40% respectively. This change was paralleled by a 27% reduction in hepatic apo B-100 mRNA. To investigate a potential mechanism of CGS 23425 action, we measured in vitro apo B mRNA editing activity in hepatocellular extract from control or CGS 23425-treated rats. Treatment with CGS 23425 increased activity of the hepatic apo B-100 editosome, apobec-1. In human hepatoma cells which lack apobec-1 activity, apo B-100 mRNA levels remained the same in cells treated with or without the agent. In summary, these observations show that CGS 23425 decreases the levels of apo B-100 in rats. This action of CGS 23425 involves apo B-100 mRNA editing activity.


Asunto(s)
Anticolesterolemiantes/farmacología , Apolipoproteínas B/sangre , Glioxilatos/farmacología , Triyodotironina/farmacología , Desaminasas APOBEC-1 , Animales , Apolipoproteína B-100 , Apolipoproteínas B/genética , Citidina Desaminasa/fisiología , Humanos , Hipercolesterolemia/sangre , Hígado/metabolismo , Masculino , Periodo Posprandial , Edición de ARN/efectos de los fármacos , ARN Mensajero/antagonistas & inhibidores , Ratas , Ratas Sprague-Dawley , Triglicéridos/sangre , Células Tumorales Cultivadas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...